Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-977-6 | CAS number: 130-15-4
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Only standard information required at REACH Annex VIII is available for assessing the toxicokinetics for the test substance. The available test data do not permit extensive conclusions concerning absorption, metabolism or excretion to be conclusively drawn. Acute toxicity via the oral route was observed although low toxicity was observed in the available OECD 422 study (repeated dose/repro screening study) which was conducted at the maximum tolerable dose owing to the corrosive nature of the test substance. An in vivo chromosome aberration assay conducted in Chinese Hamsters demonstrated exposure with clinical signs and mortality evident.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
Additional information
Repeated oral administration of the test substance (in an OECD 422 study) to rats provided a parental NOAEL of 2 mg/kg/day. This was the maximum feasible dose that could be tested owing to the corrosive nature of the test substance. In a previously conducted acute oral toxicity study (preceding current testing guidelines) and in the range finder for the OECD 422 study, symptoms of corrosive effects and systemic toxicity were noted indicating that absorption and distribution of the test substance can be expected at doses where corrosive effects are observed. Based on the relatively low Log Kow values (<4.5), bioaccumulation of the test substance is not expected.
Acute oral toxicity of the test substance was observed (LD50 124 mg/kg) alongside acute toxicity via inhalation (although lacking the required detail for REACH purposes).
No treatment related changes were observed in any of the developmental or reproductive parameters in the OECD 422 study, possibly indicating low adsorption through the placenta to directly affect the foetuses and similarly as no effects were observed in pups during the lactation phase, low exposure to the developing pups via lactation is likely. This may be a result of the low feasible dose that was used on study.
The single dose in vivo chromosome aberration study in Chinese Hamsters provided evidence of adsorption and systemic exposure as significant clinical signs were noted alongside mortality.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
